Greenwich LifeSciences (GLSI) Stock Price, News & Analysis

Company Overview

Greenwich LifeSciences, Inc. (NASDAQ: GLSI) is a clinical-stage biotechnology company focused on the development of novel immune modulators for the treatment of cancer and autoimmune diseases. The company’s product pipeline includes candidates engineered to activate or regulate key components of the innate and adaptive immune systems, with programs advancing through preclinical and early-stage clinical studies.

Headquartered in Greenwich, Connecticut, Greenwich LifeSciences conducts its research and development activities primarily in the United States. The company leverages proprietary technologies to identify immune-modulating compounds and works with contract research organizations to support its preclinical and clinical programs.

Greenwich LifeSciences pursues strategic collaborations and licensing arrangements to expand its scientific expertise and accelerate the progress of its therapeutic candidates. With a focus on unmet medical needs in oncology and inflammatory disorders, the company aims to bring first-in-class or best-in-class treatments to patients through disciplined clinical development and regulatory strategies.

Key Stats

• Today's Range: $11.20 to $11.58
• 50-Day Range: $10.07 to $12.49
• 52-Week Range: $8.06 to $15.50
• Volume: 58,517 shs
• Average Volume: 52,909 shs
• Market Capitalization: $153.06 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $42.00
• Consensus Rating: Buy

Greenwich LifeSciences Stock Analysis - MarketRank™

Greenwich LifeSciences scored higher than 31% of companies evaluated by MarketBeat, and ranked 832nd out of 958 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Buy

Consensus Rating

Greenwich LifeSciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Upside Potential

Greenwich LifeSciences has a consensus price target of $42.00, representing about 274.0% upside from its current price of $11.23.

Amount of Analyst Coverage

Greenwich LifeSciences has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Greenwich LifeSciences are expected to decrease in the coming year, from ($0.80) to ($0.81) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Greenwich LifeSciences is -8.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Greenwich LifeSciences is -8.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Greenwich LifeSciences has a P/B Ratio of 59.11. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

17.51% of the float of Greenwich LifeSciences has been sold short.

Short Interest Ratio / Days to Cover

Greenwich LifeSciences has a short interest ratio ("days to cover") of 18.2, which indicates bearish sentiment.

Change versus previous month

Short interest in Greenwich LifeSciences has recently increased by 0.94%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Greenwich LifeSciences does not currently pay a dividend.

Dividend Growth

Greenwich LifeSciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

17.51% of the float of Greenwich LifeSciences has been sold short.

Short Interest Ratio / Days to Cover

Greenwich LifeSciences has a short interest ratio ("days to cover") of 18.2, which indicates bearish sentiment.

Change versus previous month

Short interest in Greenwich LifeSciences has recently increased by 0.94%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 2.4 / 5
• News Sentiment: 0.35

News Sentiment

Greenwich LifeSciences has a news sentiment score of 0.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.92 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 9 news articles for Greenwich LifeSciences this week, compared to 2 articles on an average week.

Search Interest

Only 2 people have searched for GLSI on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

10 people have added Greenwich LifeSciences to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Greenwich LifeSciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

51.67% of the stock of Greenwich LifeSciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 4.16% of the stock of Greenwich LifeSciences is held by institutions.

GLSI Stock Analysis - Frequently Asked Questions

How have GLSI shares performed this year?

Greenwich LifeSciences' stock was trading at $11.23 at the beginning of 2025. Since then, GLSI shares have increased by 0.0% and is now trading at $11.23.

How were Greenwich LifeSciences' earnings last quarter?

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) issued its quarterly earnings results on Thursday, August, 14th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.24) by $0.06.

When did Greenwich LifeSciences IPO?

Greenwich LifeSciences (GLSI) raised $7 million in an initial public offering on Friday, September 25th 2020. The company issued 1,300,000 shares at $5.75 per share. Aegis Capital served as the underwriter for the IPO.

Who are Greenwich LifeSciences' major shareholders?

Top institutional shareholders of Greenwich LifeSciences include Geode Capital Management LLC (1.04%), Marshall Wace LLP (0.42%) and Police & Firemen s Retirement System of New Jersey (0.02%). Insiders that own company stock include Snehal Patel and Jaye Thompson.
View institutional ownership trends.

How do I buy shares of Greenwich LifeSciences?

Shares of GLSI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Greenwich LifeSciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Greenwich LifeSciences investors own include Zomedica (ZOM), Jumia Technologies (JMIA), Tesla (TSLA), Advanced Micro Devices (AMD), Netflix (NFLX), Meta Platforms (META) and NVIDIA (NVDA).

Company Calendar

• Last Earnings: 8/14/2025
• Today: 9/13/2025
• Next Earnings (Estimated): 11/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:GLSI
• CIK: 1799788
• Web: www.greenwichlifesciences.com
• Phone: 832-819-3232
• Fax: N/A
• Employees: 3
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Greenwich LifeSciences: $42.00
• High Price Target: $45.00
• Low Price Target: $39.00
• Potential Upside/Downside: +274.0%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.36)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$15.79 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -700.90%
• Return on Assets: -455.64%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.85
• Quick Ratio: 1.85

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.19 per share
• Price / Book: 59.11

Miscellaneous

• Outstanding Shares: 13,630,000
• Free Float: 6,587,000
• Market Cap: $153.06 million
• Optionable: Not Optionable
• Beta: 1.66